DC Chemicals

All products / DC7324

Amuvatinib (MP-470)
CAT. NO. DC7324

Amuvatinib (MP-470)

Pack sizes and prices

Pack sizePrice
100 mg$450 USDRequest a quote →
250 mg$800 USDRequest a quote →
1 g$1,500 USDRequest a quote →
10 mM * 1 mL in DMSO$150 USDRequest a quote →

In stock. Contact our team for lead time, shipping and final quotation.

Product overview

Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively.

For research use only. Results depend on experimental conditions and do not constitute a performance guarantee.

Identity and specifications

Catalog numberDC7324
Product nameAmuvatinib (MP-470)
CAS850879-09-3
Molecular formulaC23H21N5O3S
Molecular weight447.5095
Purity>98%
SMILESS=C(N([H])C([H])([H])C1C([H])=C([H])C2=C(C=1[H])OC([H])([H])O2)N1C([H])([H])C([H])([H])N(C2C3=C(C4=C([H])C([H])=C([H])C([H])=C4O3)N=C([H])N=2)C([H])([H])C1([H])[H]

Source-listed specifications; the batch COA applies.

Source and product documents

The supplier source is linked below. Contact us for COA, SDS and batch-specific documents.

DC Chemicals — Amuvatinib (MP-470) (DC7324)

Source references

[1]. Bearss DJ, et al. US Patent, US/2008/0226747. [2]. Hurley LH, et al. World Patent, WO/2005/037825. [3]. Mahadevan D, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene, 2007, 26(27), 3909-3919. [4]. Qi W, et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer, 2009, 9, 142.

Related research products